Efficacy of Aspirin in Preventing Venous Thromboembolism

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 24, 2022

Primary Completion Date

October 24, 2022

Study Completion Date

February 28, 2023

Conditions
Venous Thromboembolism (VTE)Total Joint ArthroplastyTotal Hip Arthroplasty (THA)
Interventions
DRUG

Aspirin

100 mg/day orally for 25 days

DRUG

enoxaparin

40 mg/day subcutaneously for 28 days, with the dose reduced to 20 mg for patients weighing less than 50 kg or with an estimated glomerular filtration rate less than 30 mL/min/1.73 m².

Trial Locations (1)

72450

ISSSTEP, Puebla City

All Listed Sponsors
lead

Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado

OTHER_GOV